Insulin secretion improvement

Insulin secretion improvement is a physiological process and therapeutic goal rather than a single molecular target (NIH, 2023). It involves the enhancement of insulin release from the beta cells of the islets of Langerhans in the pancreas, typically to counteract the insulin deficiency or resistance seen in Type 2 Diabetes Mellitus (StatPearls, 2024). This process is regulated by various signaling pathways, including the incretin system and glucose-sensing mechanisms (PubMed, 2022). Pharmacological agents that improve insulin secretion act on specific targets like the Glucagon-like peptide 1 receptor or the Sulfonylurea receptor to stimulate the exocytosis of insulin-containing granules (Nature Reviews Endocrinology, 2021). Achieving this improvement is critical for maintaining glycemic control and preventing long-term microvascular and macrovascular complications of diabetes (American Diabetes Association, 2023). Therapeutic strategies often focus on restoring the first-phase insulin response, which is frequently lost in early-stage diabetes (PubMed, 2021). By targeting these pathways, clinicians aim to reduce postprandial glucose excursions and improve overall metabolic health (NIH, 2023).

Other names

Enhancement of insulin releaseBeta-cell secretagogue effectInsulinotropic effectImprovement of beta-cell function

This is a physiological outcome achieved through various molecular mechanisms, including the activation of the Glucagon-like peptide 1 receptor (GLP-1R), closure of ATP-sensitive potassium (K-ATP) channels on beta cells, or inhibition of the Dipeptidyl peptidase-4 (DPP-4) enzyme to prolong the activity of endogenous incretins (StatPearls, 2024; PubMed, 2022).